Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors

Clinical Transplantation

Volumn 28, Issue 9, 2014, Pages 1054-1060

  Perbos, Emma ^a   Juinier, Estelle ^a   Guidicelli, Gwendaline ^a   Dromer, Claire ^a   Merville, Pierre ^a,b   Billes, Marc Alain ^a   Taupin, Jean Luc ^a,b   Neau Cransac, Martine ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b CNRS Bordeaux Segalen University   (France)

Author keywords

Donor specific anti HLA antibodies; Everolimus; Minimization of calcineurin inhibitors; mTOR inhibitor

Indexed keywords

CYCLOSPORIN; DONOR SPECIFIC ANTIBODY; EVEROLIMUS; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; CALCINEURIN INHIBITOR; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CARDIAC GRAFT REJECTION; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DONOR; DOSE RESPONSE; DRUG COMBINATION; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR;

CALCINEURIN INHIBITORS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TISSUE DONORS; TRANSPLANT RECIPIENTS;

EID: 84908371205     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12418     Document Type: Article

References (23)

1. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 2012: 94: 659.
2. Gullestad L, Mortensen SA, Eiskjaer H etal. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010: 90: 1581.
3. Lebranchu Y, Thierry A, Thervet E etal. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the postconcept study: renal function after early CsA-to-SRL conversion. Am J Transplant 2011: 11: 1665.
4. Lebranchu Y, Thierry A, Toupance O etal. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3months after renal transplantation: concept study. Am J Transplant 2009: 9: 1115.
5. Saliba F, De Simone P, Nevens F etal. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013: 13: 1734.
6. Euvrard S, Morelon E, Rostaing L etal. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012: 367: 329.
7. De Simone P, Crocetti L, Pezzati D etal. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2014: 46: 241.
8. Campistol JM. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
9. Liefeldt L, Brakemeier S, Glander P etal. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation: DSA risk and immunosuppression after KTX. Am J Transplant 2012: 12: 1192.
10. Kamar N, Del Bello A, Congy-Jolivet N etal. Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen. Clin Transplant 2013: 27: 455.
11. Cibrik D, Silva HT, Vathsala A etal. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24months in renal transplantation. Transplantation 2013: 95: 933.
12. Eisen HJ, Kobashigawa J, Starling RC etal. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial: everolimus versus MMF in heart transplantation. Am J Transplant 2013: 13: 1203.
13. Sharif A, Shabir S, Chand S etal. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011: 22: 2107.
14. Mao Q, Terasaki PI, Cai J etal. extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007: 7: 864.
15. Wiebe C, Gibson IW, Blydt-Hansen TD etal. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant: clinical pathologic correlations of de novo DSA. Am J Transplant 2012: 12: 1157.
16. Cooper JE, Gralla J, Cagle L etal. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011: 91: 1103.
17. Snyder LD, Wang Z, Chen D-F etal. Implications for human leukocyte antigen antibodies after lung transplantation. Posttransplant human leukocyte antigen antibodies a 10-year experience in 441 patients. Chest 2013: 144: 226.
18. Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013: 32: 70.
19. Smith JD, Banner NR, Hamour IM etal. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival: de novo HLA antibodies after heart transplantation. Am J Transplant 2011: 11: 312.
20. Hodges AM, Lyster H, McDermott A etal. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 2012: 65: e136.
21. Musat AI, Agni RM, Wai PY etal. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation: HLA alloantibodies in liver allograft rejection. Am J Transplant 2011: 11: 500.
22. Del Bello A, Congy-Jolivet N, Muscari F etal. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients: DSA maintenance after liver transplantation. Am J Transplant 2014: 14: 867.
23. Ntokou I-SA, Iniotaki AG, Kontou EN etal. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules: post-transplant anti-HLA alloantibodies in renal transplantation. Transpl Int 2011: 24: 1084.